Investing.com - Nuvectis Pharma (NASDAQ: NVCT) reported fourth quarter EPS of $-0.41, $0.05 worse than the analyst estimate of $-0.36. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.00.
Nuvectis Pharma's stock price closed at $10.20. It is up 24.54% in the last 3 months and down -10.05% in the last 12 months.
Nuvectis Pharma saw positive EPS revisions and negative EPS revisions in the last 90 days. See Nuvectis Pharma's stock price’s past reactions to earnings here.
According to InvestingPro, Nuvectis Pharma's Financial Health score is "fair performance".
Check out Nuvectis Pharma's recent earnings performance, and Nuvectis Pharma's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar